Nanotechnology Now - Press Release: "AMAG Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference"

Home > Press > AMAG Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced Louis Brenner MD, Senior Vice President and David Arkowitz, Chief Financial Officer and Chief Business Officer, will present an overview of the Company at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1 at 8:40 a.m. ET. The conference is being held April 30 - May 2, 2008 in Key Biscayne, FL.

AMAG Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference

Cambridge, MA | Posted on April 28th, 2008

A live audio webcast of the presentation will be accessible through the Investors section of the Company's website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until May 15, 2008.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti
617-498-3362

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: